UY28260A1 - Combinación farmacéutica - Google Patents

Combinación farmacéutica

Info

Publication number
UY28260A1
UY28260A1 UY28260A UY28260A UY28260A1 UY 28260 A1 UY28260 A1 UY 28260A1 UY 28260 A UY28260 A UY 28260A UY 28260 A UY28260 A UY 28260A UY 28260 A1 UY28260 A1 UY 28260A1
Authority
UY
Uruguay
Prior art keywords
combination
pharmaceutical combination
eletriptan
prevention
treatment
Prior art date
Application number
UY28260A
Other languages
English (en)
Inventor
Michael John Humphrey
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0308469A external-priority patent/GB0308469D0/en
Priority claimed from GB0312479A external-priority patent/GB0312479D0/en
Application filed by Pfizer filed Critical Pfizer
Publication of UY28260A1 publication Critical patent/UY28260A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose

Abstract

El presente invento proporciona una combinación de (a) eletriptan, o una de sus sales farmacéuticamente aceptable, y (b) bicarbonato de sodio. La combinación proporciona una absorción rápida de eletriptan cuando se toma por vía oral. La combinación es útil para el tratamiento o la prevención de una enfermedad para la que es indicado un agente agonista de 5-HT1, particularmente en el tratamiento de una migrana o para la prevención de una recurrencia de migrana.
UY28260A 2003-04-11 2004-04-06 Combinación farmacéutica UY28260A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB0308469A GB0308469D0 (en) 2003-04-11 2003-04-11 Pharmaceutical combination
GB0312479A GB0312479D0 (en) 2003-05-30 2003-05-30 Pharmaceutical combination

Publications (1)

Publication Number Publication Date
UY28260A1 true UY28260A1 (es) 2004-11-30

Family

ID=33161221

Family Applications (1)

Application Number Title Priority Date Filing Date
UY28260A UY28260A1 (es) 2003-04-11 2004-04-06 Combinación farmacéutica

Country Status (12)

Country Link
EP (1) EP1615635A1 (es)
JP (1) JP2006522790A (es)
AR (1) AR044009A1 (es)
BR (1) BRPI0409127A (es)
CA (1) CA2521902A1 (es)
MX (1) MXPA05010070A (es)
NL (1) NL1025908C2 (es)
PA (1) PA8599901A1 (es)
PE (1) PE20050086A1 (es)
TW (1) TW200423929A (es)
UY (1) UY28260A1 (es)
WO (1) WO2004089365A1 (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090299077A1 (en) * 2008-05-22 2009-12-03 Vinod Kumar Kansal Salts of (R)-5-(2phenylsulphonylethenyl)-3-(N-methylpyrrolidin-2-ylmethyl)-1H-indole, 5-bromo-3-[(R)-1-methyl-pyrrolidin-2-ylmethyl]-1H-indole and of eletriptan
IT1393700B1 (it) 2009-04-22 2012-05-08 F S I Fabbrica Italiana Sint Sintesi di 3-{[(2r)-1-metilpirrolidin-2-il]metil}-5-[2-(fenilsulfonil)etil]-1h-indolo
JP6878021B2 (ja) * 2016-02-02 2021-05-26 第一三共ヘルスケア株式会社 トリプタンとアスコルビン酸を含有する医薬組成物
AU2019297360B2 (en) 2018-07-03 2022-07-21 Axsome Therapeutics, Inc. Pharmaceutical compositions comprising meloxicam

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1197038B (it) * 1986-08-01 1988-11-25 Zambon Spa Composizione farmaceutica ad attivita' analgesica
US5607951A (en) 1990-10-15 1997-03-04 Pfizer Inc Indole derivatives
IT1272149B (it) * 1993-03-26 1997-06-11 Zambon Spa Composizione farmeceutiche ad attivita' analgesica
GB9417310D0 (en) 1994-08-27 1994-10-19 Pfizer Ltd Therapeutic agents
US6488961B1 (en) 1996-09-20 2002-12-03 Ethypharm, Inc. Effervescent granules and methods for their preparation
GB9704524D0 (en) * 1997-03-05 1997-04-23 Smithkline Beecham Plc Composition
GB9816556D0 (en) 1998-07-30 1998-09-30 Pfizer Ltd Therapy
GB9825988D0 (en) 1998-11-27 1999-01-20 Pfizer Ltd Indole derivatives
IL136025A0 (en) * 1999-05-14 2001-05-20 Pfizer Prod Inc Combination therapy for the treatment of migraine
GB0018968D0 (en) 2000-08-02 2000-09-20 Pfizer Ltd Particulate composition
GB0105131D0 (en) * 2001-03-01 2001-04-18 Pfizer Ltd Compositions having improved bioavailability
GB0129117D0 (en) * 2001-12-05 2002-01-23 Glaxo Group Ltd Pharmaceutical composition
JP2006523620A (ja) * 2003-02-19 2006-10-19 バイオヴェイル ラボラトリーズ インコーポレイテッド 急速吸収選択的５−ｈｔ作用剤製剤

Also Published As

Publication number Publication date
EP1615635A1 (en) 2006-01-18
MXPA05010070A (es) 2005-11-23
WO2004089365A1 (en) 2004-10-21
PA8599901A1 (es) 2005-02-04
AR044009A1 (es) 2005-08-24
NL1025908A1 (nl) 2004-10-13
CA2521902A1 (en) 2004-10-21
TW200423929A (en) 2004-11-16
BRPI0409127A (pt) 2006-03-28
NL1025908C2 (nl) 2005-11-22
PE20050086A1 (es) 2005-03-01
JP2006522790A (ja) 2006-10-05

Similar Documents

Publication Publication Date Title
CY1116693T1 (el) Συνδυασμος αζελαστινης και κυκλεσονιδης
NO20045434L (no) En kombinasjon av en NMDA-antagonist og acetylkolinesteraseinhibitorer for behandlingen av Alzheimers sykdom
BR0215184A (pt) composições farmacêuticas de derivados de taxano oralmente ativos tendo biodisponibilidade aumentada
CY1109119T1 (el) Φαρμακοτεχνικες μορφες παρατεταμενης απελευθερωσης που περιλαμβανουν λαμοτριγινη
ECSP099501A (es) Formulaciones de dosis unitaria y métodos para el tratamiento de la trombosis con un inhibidor oral del factor xa
CL2004000643A1 (es) Composicion farmaceutica que comprende un agonista de 5-ht 1b/1d y un inhibidor selectivo de ciclooxigenasa-2, util en el tratamiento de la migrana.
GT200500309A (es) Derivados de sulfonilbencilimidazol
NO20082088L (no) Azetidiner som MEK-inhibitorer for behandling av proliferative sykdommer
AR041089A1 (es) Procedimiento y composiciones farmaceutiicas para tratar aterosclerosis, dislipidemias y afecciones relacionadas
ECSP003652A (es) TRATAMIENTO DE COMBINACION CON I1-1ra Y COMPUESTOS QUE INHIBEN EL PROCESAMIENTO Y LA LIBERACION DE I1-1
AR054253A1 (es) Asociacion entre la ferroquina y un derivado de artemisinina para el tratamiento del paludismo
CY1110130T1 (el) Παραγωγα μορφολινης για χρηση ως αγωνιστες ντοπαμινης στην θεραπευτικη αγωγη σεξουαλικης δυσλειτουργιας i.α.
CL2003002653A1 (es) Composicion farmaceutica que comprende (a) un antiinflamatorio no esteroidal (nsaid), preferentemente ibuprofeno, (b) un descongestionante, preferentemente pseudoefedrina y (c) un antihistaminico, preferentemente clorfeniramina; metodo para su prepar
UY28260A1 (es) Combinación farmacéutica
GT200100149A (es) Composicion de eletriptan en forma de particulas.
MA27262A1 (fr) Microcapsules pour la liberation retardee et controlee du perindopril
BR9912588A (pt) Prevenção de recorrência de enxaqueca
AR038305A1 (es) Composicion farmaceutica dispersable oralmente de perindopril
PA8552301A1 (es) Metodo para el tratamiento de insomnio primario
AR038858A1 (es) Combinacion
CR9074A (es) Agente para la profilaxis o tratamiento del sindrome metabolico
DOP2004000871A (es) Combinacion farmaceutica
AR039162A1 (es) Formulaciones de venlafaxina de liberacion extendida
DK1575362T3 (da) Anvendelse af et acaricidpulver
CL2004000751A1 (es) Combinacion farmaceutica que contiene (a) eletripan, o una de sus sales, y (b) bicarbonato de sodio; composicion y producto farmaceutico que contiene a dicha combinacion; y su uso en la preparacion de un medicamento util para el tratamiento y la prev

Legal Events

Date Code Title Description
109 Application deemed to be withdrawn

Effective date: 20150521